Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Placebo 1 to Probiotic A
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastrointestinal Dysfunction
1 trial -
Placebo and Escitalopram
Takeda
Panic Disorder
1 trial -
Placebo plus high-intensity statin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Coronary Syndrome
1 trial -
Platelet-rich plasma
COLLEGIUM PHARMACEUTICAL, INC
ACL Injury
1 trial -
Prebiotic Fiber Supplement + loperamide hydrochloride capsule
The First People's Hospital of Lianyungang
Chemotherapy-related Diarrhea
1 trial -
Preoperative three-dimensional reconstruction
Universal Integrated
Kidney Neoplasms / Surgery
1 trial -
Pulsed dye laser (PDL)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Port Wine Stain
1 trial -
R-CDOP
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
RB001
The First People's Hospital of Lianyungang
Phelan-McDermid Syndrome
1 trial -
REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]
Hospital Authority, Hong Kong
Hemodynamic Instability
1 trial -
Radiotherapy combined with TKI and Anti-PD-1 Antibody
Jian Li
Stage IIIA Hepatocellular Carcinoma
1 trial -
Regen Matrix-PRP-XLHA
Regeneron Ireland Designated Activity Company (DAC)
Knee Osteoarthritis
1 trial -
Regional lymph node radiotherapy (RNI) including the axilla
The First People's Hospital of Lianyungang
Axillary Lymph Node Dissection
1 trial -
Remimazolam
The First People's Hospital of Lianyungang
Sedation and Analgesia
1 trial -
Remimazolam Tosilate
The First People's Hospital of Lianyungang
Frailty
1 trial -
Remimazolam besylate
The First People's Hospital of Lianyungang
Remimazolam
1 trial -
Resveratrol, curcumin
Atrium Therapeutics
Effect of Resveratrol and Curcumin on Inflammation
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ventricular Mural Thrombosis
1 trial -
Ropivacaine
Zealand Pharma A/S
Pain, Postoperative
1 trial -
Routine IOP-lowering medications
Zhongshan Ophthalmic Center, Sun Yat-sen University
Open Angle Glaucoma
1 trial -
SGLT2 inhibitor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Kidney Transplantation
1 trial -
Sapropterin
BioMarin Pharmaceutical Australia Pty Ltd
Hyperphenylalaninemia
1 trial -
Saturated fat
United Therapeutics Europe Ltd
Cardiovascular Disease
1 trial -
Seasonal malaria chemoprevention
United Therapeutics Europe Ltd
Malaria
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources